Slow Parkinson progression with telmisartan
- Trial ID
- NCT07207057
- Official Title
- Edmond J Safra, Accelerating Clinical Trials in Parkinson's Disease (EJS ACT-PD) - a Multi-arm Multi-stage Platform Trial for Potential Disease Modifying Approaches.
- Goal
- Slow Parkinson progression with telmisartan
- Phase
- PHASE3
- Status
- RECRUITING
- Sponsor
- University College, London
- Study Type
- INTERVENTIONAL
- Enrollment
- 1200 participants
- Conditions
- Parkinsons Disease (PD)
- Interventions
- Placebo, Telmisartan, Terazosin (Hytrin)
Plain-Language Summary
The goal is to see if two repurposed drugs can slow Parkinson's progression and protect neurons, offering possible disease modification rather than only treating symptoms. Telmisartan blocks angiotensin II type 1 receptors to lower blood pressure and may reduce brain inflammation and oxidative stress, so it would be taken alongside usual Parkinson's medicines like levodopa with monitoring of blood pressure, potassium and kidney function. Terazosin is an alpha-1 blocker that also activates the enzyme PGK1 to boost cellular energy and ATP in neurons, which could make cells more resilient; it can cause dizziness or low blood pressure so people on other alpha blockers or with symptomatic hypotension are excluded. The trial is enrolling about 1,200 adults aged 30 and up with neurologist-diagnosed Parkinson's who have been on levodopa or a dopamine agonist for at least two months, excluding those with dementia, certain genetic forms, recent experimental drug exposure, serious heart or kidney disease, problematic low blood pressure, or pregnancy.
Locations
- UCLH, London, United Kingdom
- Clinical Ageing Research Unit, Newcastle, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Placebo. The goal is to see if two repurposed drugs can slow Parkinson's progression and protect neurons, offering possible disease modification rather than only treating symptoms. Telmisartan blocks angiotensin II type 1 receptors to lower blood pressure and may reduce brain inflammation and oxidative stress, so it would be taken alongside usual Parkinson's medicines like levodopa with monitoring of blood pressure, potassium and kidney function. Terazosin is an alpha-1 blocker that also activates the enzyme PGK1 to boost cellular energy and ATP in neurons, which could make cells more resilient; it can cause dizziness or low blood pressure so people on other alpha blockers or with symptomatic hypotension are excluded. The trial is enrolling about 1,200 adults aged 30 and up with neurologist-diagnosed Parkinson's who have been on levodopa or a dopamine agonist for at least two months, excluding those with dementia, certain genetic forms, recent experimental drug exposure, serious heart or kidney disease, problematic low blood pressure, or pregnancy.
- Who can participate?
- Participants must be at least 30 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 3 trial is estimated to last approximately 5 years and 8 months.